Literature DB >> 1677013

Eosinophil infiltration: effects of H1 antihistamines.

R Fadel1, B David, R Rassemont, N Herpin-Richard, A Borgnon, J P Rihoux.   

Abstract

This article reviews the contribution of cell-mediated inflammatory responses to the immediate immunoglobulin E-dependent allergic reaction. Apparently eosinophils play an important part in the pathogenesis of allergic reactions. Some new H1 antihistamines may also have non-H1-mediated antiinflammatory properties. In two double-blind, placebo-controlled, crossover studies of allergic and normal subjects, we showed that oral cetirizine, at dosages of 10 and 20 mg/day, significantly inhibited wheal-and-erythema reactions induced by grass pollen, 48/80, histamine, platelet-activating factor acether, and N-formyl-methionyl-leucyl-phenylalanine. In the first study, cutaneous eosinophil migration was significantly inhibited by cetirizine at pollen and 48/80 skin test sites (61%, p less than 0.01, and 53%, p less than 0.01, respectively), although no change was observed at histamine skin test sites. Inhibition of neutrophil accumulation was also observed at pollen and 48/80 sites (41%, p less than 0.1, and 31%, p less than 0.1, respectively). Monocyte accumulation was not affected by cetirizine. In the second study, cetirizine suppressed the eosinophil influx induced by pollen, platelet-activating factor, 400 ng, and platelet-activating factor, 40 ng (63%, p less than 0.001; 58.5%, p less than 0.001; and 57.8%, p less than 0.01, respectively). This inhibition was effective 2 hours after challenge and persisted through hours 4, 8, and 24. N-Formyl-methionyl-leucyl-phenylalanine induced a weak eosinophil accumulation that was inhibited by cetirizine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1677013     DOI: 10.1016/0190-9622(91)70164-w

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  2 in total

Review 1.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Open-label, add-on trial of cetirizine for neuromyelitis optica.

Authors:  Ilana Katz Sand; Michelle T Fabian; Russell Telford; Thomas A Kraus; Mirna Chehade; Madhan Masilamani; Thomas Moran; Colleen Farrell; Shelly Ebel; Lawrence J Cook; John Rose; Fred D Lublin
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-02-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.